Nimodipine (GTx-104)
Small molecule
Evidence outlook · regulatory review
Subarachnoid Hemorrhage: FDA issued a complete response letter (2026-04-23)
FDA issues complete response letter for the GTx-104 NDA. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other L-type calcium channels (Cav1.2) drugs
Nimodipine (Nimotop), Lercanidipine. Compare all 3 L-type calcium channels (Cav1.2) drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Subarachnoid Hemorrhage: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nimodipine (GTx-104): this drug | Phase 3 | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Nimodipine (Nimotop) | ApprovedUS marketing discontinued | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Lercanidipine | —(overall) | Small molecule | L-type calcium channels (Cav1.2) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent